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Abstract: Because of the pathological role of IL-6 in rheumatoid arthritis (RA), tocilizumab (TCZ), a humanized anti-IL-6 receptor 
monoclonal antibody, was expected to improve inflammation and joint destruction of RA. Indeed, randomized clinical trials demon-
strated the clinical efficacy of TCZ as monotherapy or combined with methotrexate (MTX) for RA patients with inadequate responses 
to disease-modifying antirheumatic drugs, MTX or tumor necrosis factor (TNF) inhibitors. Although long-term tolerability for TCZ 
is superior to that for TNF inhibitors, information regarding the potency of drug free remission of TCZ is limited at present. In terms 
of its safety profile, the general risk of infection when using TCZ is comparable to that of TNF inhibitors. TCZ has some advantage in 
RA patients who can not use MTX and are non-responders to TNF inhibitors. In conclusion, TCZ is one of the most prospective next 
generation biologics for the treatment of RA.
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Introduction
Interleukin  (IL)-6  was  originally  cloned  as  a  B 
cell  differentiation  factor  that  promotes  B  cell 
differentiation  into  antibody-producing  cells.1 
Subsequent  in  vitro  studies  and  analysis  of  IL-6 
transgenic mice have shown that IL-6 acts not only on 
B cells but also on T cells, hepatocytes, hematopoietic 
progenitor  cells  and  various  other  cells.2–4  One  of 
the important functions of IL-6 is induction of the 
differentiation of CD4+ naïve T cells into effector 
cells. IL-6 promotes naïve T cell differentiation into 
Th17 cells in the presence of transforming growth 
factor  (TGF)-β,  while  it  inhibits  TGF-β-induced 
regulatory T cell (Treg) differentiation.5 IL-6 is also 
reported to be able to induce the switching of Treg 
into  Th17  cells. An  imbalance  between  Th17  and 
Treg is considered to be the primary pathogenesis 
of  several  autoimmune  diseases.6  Based  on  these 
findings, it was anticipated that IL-6 blockage would 
constitute a novel treatment strategy for autoimmune 
and  inflammatory  diseases.4,7–9  Tocilizumab  (TCZ) 
was developed to this end. TCZ is a humanized anti-
IL-6 receptor (IL-6R) monoclonal antibody (Ab) of 
the  IgG1  class  that  was  generated  by  grafting  the 
complementarity-determining  regions  of  a  mouse 
anti-human IL-6R Ab onto human IgG1. TCZ blocks 
all IL-6-mediated signals by inhibiting IL-6 binding 
to transmembrane and soluble IL-6Rs.
Mechanism of Action, Metabolism  
and Pharmacokinetic Profile
Rheumatoid arthritis (RA) is a chronic, progressive 
inflammatory disease of the joints and surrounding 
tissues  accompanied  by  intense  pain,  irreversible 
joint destruction and systemic complications such as 
fatigue, anemia and fever.10 Within joints, inflamma-
tory cells invade the synovium, which is accompa-
nied by neovascularization. Synoviocyte hyperplasia 
then forms synovitis, the so-called pannus. Activated 
  synovitis  causes  destruction  of  cartilage  and  ero-
sion of the adjacent bone. Increased IL-6 levels in 
the sera and synovium of RA patients and proinflam-
matory activities of IL-6 such as augmentation of 
synovial fibroblast proliferation, osteoclast differen-
tiation, and the production of matrix metalloprotei-
nase (MMP) and vascular endothelial growth factor 
(VEGF) indicate that IL-6 is involved in the patho-
genesis of RA.11–16
Induction  of  type  II  collagen-induced  arthritis 
(CIA) requires CD4 T cells and leads to the produc-
tion of anti-type II collagen IgG. The incidence and 
severity of arthritis of CIA was reduced following IL-6 
blockade, which was achieved by gene knockout or 
by administration of an anti-IL-6R Ab.17–22 In contrast, 
the arthritis of another arthritis model termed anti-
type II collagen antibody-induced arthritis (CAIA) 
has skipped the priming phase of T cell dependent 
antibody generation. Although IL-6 is elevated in both 
models, CAIA was profoundly suppressed in tumor 
necrosis factor (TNF) -/- mice but not in IL-6-/- mice, 
indicating that TNF might play a more significant role 
in the development of CAIA than IL-6.23 This obser-
vation suggests that, in this model, IL-6 is required for 
activation of T cell responses and for the production 
of antibodies specific for joint components (priming 
phase) and that TNF is necessary for the generation 
of arthritis (effector phase).24 We found that TCZ was 
not effective for two patients with psoriatic arthritis.25 
This  type  of  arthritis,  unlike  rheumatoid  arthritis, 
does not appear to require immune activation for its 
development. Figure 1 shows the pathologic role of 
IL-6 in the development of RA. IL-6 contributes to 
immune activation of RA and systemic inflammation 
while TNF mainly contributes to arthritis and joint 
destruction.
Recommended  TCZ  dosing  regimens  differ 
depending  on  the  area.  In  European  countries  and 
Japan TCZ is administered intravenously at a dose 
of 8 mg/kg every 4 weeks. In the USA, it is recom-
mended  that  TCZ  should  be  initially  administered 
at a dose of 4 mg/kg every 4 weeks and it is then 
permitted to increase the dose up to 8 mg/kg every 
4 weeks if clinically indicated. At steady state, the 
elimination half-life of TCZ at a dose of 4 mg/kg and 
8 mg/kg is 11 days and 13 days, respectively.26 Serum 
TCZ levels of more than 1 µg/mL are recommended 
to maintain sufficient efficacy. The level of serum 
CRP is a good marker for titration of TCZ. Thus, if 
serum concentrations of TCZ exceed 1 µg/mL at the 
trough level, this means that IL-6 function is blocked 
in vivo and therefore CRP levels are within the nor-
mal range. An increase in CRP level suggests that 
inhibition of IL-6 function by TCZ is not   complete. 
Although  at  the  present  time  it  is  not  indicated, 
dose-up or interval shortening of TCZ administration 
might produce   better outcome. TCZ administration at Tocilizumab for the treatment of rheumatoid arthritis
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2-week   intervals is approved in Japan for treatment of 
  Castleman’s disease and systemic juvenile idiopathic 
arthritis, in which a large amount of IL-6 in the sera 
was found. In addition to its effect on the amount of 
IL-6 production, the rate of TCZ degradation also 
influences the efficacy of TCZ. We found that more 
TCZ is required when patients have   splenomegaly.27 
Studies  of  TCZ  tissue  distribution  in  cynomol-
gus monkeys demonstrated that high levels of TCZ 
remain not only in synovial fluid and plasma but also 
in spleen for up to 28 days after TCZ administration. 
Excessive accumulation of TCZ in spleen may reduce 
the anti-rheumatic effect of TCZ.
During TCZ therapy, the serum IL-6 concentration 
temporarily increases. The so-called “bathtub theory”, 
as shown in Figure 2, illustrates this phenomenon.28 
TCZ does not directly inhibit the production of IL-6. 
As long as free TCZ is detectable, soluble IL-6R is 
saturated with TCZ and IL-6 signaling is completely 
inhibited. Free serum IL-6 increases because IL-6R 
mediated binding of IL-6 is inhibited by the unavailabil-
ity of TCZ-free IL-6R. Although systemic inflamma-
tion is immediately blocked by TCZ, IL-6 production 
is not inhibited until immune stabilization is induced 
by TCZ. Normalization of serum IL-6 level suggests 
repair of the immunological abnormality and indeed 
clinical remission is achieved in such RA patients.
Phase I-III Clinical Trials
Phase I and II clinical trials of TCZ have been per-
formed and were reported between 2002 and 2006. 
Summaries of phase I/II trials are shown in Table 1. 
The first trial was performed in the UK29 using sin-
gle administration of a placebo or TCZ at a dosage 
of 0.1, 1, 5 or 10 mg/kg. Patients who were treated 
with 5 mg/kg or 10 mg/kg of TCZ showed signifi-
cant  improvement  at  week  2.  After  pharmacoki-
netic assessment,30 a study for dose setting trial was 
performed  in  Japan.31  Patients  were  administered 
TCZ (4 or 8 mg/kg) monotherapy or placebo every 
4 weeks. Both doses of TCZ were effective but the 
8 mg/kg dose group showed a greater improvement 
than the 4 mg/kg dose group.
The  CHARISMA  study  (Chugai  Humanized 
  Anti-Rheumatic  Interleukin  Six  Monoclonal  Anti-
body) was performed in Europe.32 Active RA patients 
with  an  inadequate  response  (IR)  to  methotrexate 
(MTX) were randomly divided into one of the fol-
lowing seven treatment arms: TCZ at a dose of 2, 4 or 
8 mg/kg that was administered either as monotherapy 
or in combination with MTX, or MTX plus a placebo. 
At week 16, the American College of Rheumatol-
ogy (ACR) criteria for 20% improvement (ACR20) 
response was better in the 4 mg/kg and 8 mg/kg TCZ 
groups with or without MTX than in the group of 
patients that received the placebo plus MTX. Anti-
TCZ antibodies were produced in approximately 25% 
of the TCZ 2 mg/kg monotherapy group.
To investigate the long-term safety and efficacy 
of TCZ, the STREAM study (the Long-term Safety 
and Efficacy of Tocilizumab, an Anti-IL-6 Receptor 
Monoclonal Antibody, in Patients with Rheumatoid 
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Figure 1. The pathological role of IL-6 in RA.
Notes: The pathogenesis of rheumatoid arthritis is composed of a priming phase and an effector phase. In the   priming phase, IL-6-induced Th17 
development and the induction of autoantibodies such as rheumatoid factor (RF) are important. Th17-dependent immune activation generates active 
synovitis. Synovitis is an epicenter of the inflammation of RA. Systemic inflammation (production of acute phase protein, anemia and fatigue) is mainly 
mediated by IL-6. Local inflammation (arthritis) such as arthralgia, swelling, and joint destruction is mainly mediated by TNF.Ogata et al
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Arthritis) was performed in Japan.33 Patients received 
TCZ  monotherapy  (8  mg/kg)  that  was  adminis-
tered every 4 weeks over a 5-year period. Overall, 
32 patients (22%) withdrew from the study due to 
adverse events (AEs). After 5 years, 84.0, 69.1 and 
43.6% of the patients met improvement criteria for 
ACR20, ACR50 and ACR70, respectively.
As shown in Table 2, seven phase III randomized 
clinical  trials  (RCTs)  under  various  clinical  situa-
tions have been conducted to evaluate the efficacy 
and safety of TCZ therapy of RA patients. In these 
studies, the TCZ dose was set as monthly administra-
tion at a dose of 4 or 8 mg/kg, based on the results of 
phase I and II studies.
The AMBITION trial (Actemra versus Methotrex-
ate double-Blind Investigative Trial In mONotherapy) 
demonstrated that TCZ monotherapy is better than 
MTX monotherapy, showing rapid improvement in 
RA signs and symptoms, and a favorable benefit-risk, 
in patients for whom treatment with MTX or biologi-
cal agents had not previously failed.34
The OPTION trial (Tocilizumab Pivotal Trial in 
Methotrexate Inadequate RespONders)   demonstrated 
that TCZ in combination with MTX was effective 
and  well  tolerated  in  patients  with  moderate  to 
severe  active  RA  that  had  an  inadequate  response 
to MTX.35,36
The TOWARD trial (Tocilizumab in cOmbination 
With traditional DMARD therapy) demonstrated that 
TCZ combined with any of the disease modifying 
antirheumatic drugs (DMARDs) (MTX, chloroquine, 
gold, sulphasalazine, azathioprine or leflunomide) was 
safe and effective in reducing articular and systemic 
symptoms in patients with an inadequate response to 
these DMARDs.37
The RADIATE trial (RheumAtoiD ArthrItis study 
in Anti-TNF failurEs) demonstrated that TCZ plus 
MTX was effective in achieving rapid and sustained 
improvements in signs and symptoms in patients with 
an adequate response to TNF antagonists and had a 
manageable safety profile.38
The LITHE trial (TociLIzumab Safety and THE 
Prevention of Structural Joint Damage) demonstrated 
that TCZ plus MTX had superior ACR20 responses at 
24 weeks compared with controls treated with placebo 
plus  MTX  and  significantly  inhibited    radiographic 
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Figure 2. Mechanism of action of tocilizumab in RA (bathtub theory). 
Notes: The mechanism of tocilizumab (TCZ) in rheumatoid arthritis was illustrated as the bathtub theory by Nishimoto et al.28 The faucet (immune cells) 
supplies IL-6 into the bathtub (blood). Under normal conditions, the supplied IL-6 is completely cleared by soakaway (catabolism), there is no IL-6 over-
flow into the IL-6 receptor system (drain) and there is no IL-6 function. In RA, the faucet is fully opened and soakaway cannot completely eliminate the 
increased production of IL-6. Therefore IL-6 overflows into the drain and IL-6 acts   pleiotropically. This IL-6 induces immune activation and systemic inflam-
mation through the IL-6R system. After TCZ therapy, the drain is blocked.   However, IL-6 is not eliminated from the blood. Although the IL-6 cannot act 
through its receptors, the serum IL-6 level is increased because soakaway cannot completely eliminate IL-6. Thus, IL-6 function is blocked by TCZ and 
inflammation is suppressed. Immune starvation by TCZ gradually closes the faucet (clinical remission). The IL-6 supply is stopped and serum IL-6 levels 
revert to normal. Compete starvation of immune activation may lead to cessation of TCZ treatment (drug-free remission).Tocilizumab for the treatment of rheumatoid arthritis
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progression at 52 weeks in patients with an   inadequate 
clinical response to MTX.39
The  SAMURAI  (Study  of  Active  Controlled 
Monotherapy  Used  for  Rheumatoid  Arthritis, 
an  IL-6  inhibitor)  trial  demonstrated  that  TCZ 
  monotherapy is generally well tolerated and provides 
radiographic benefit at 52 weeks in patients with an 
inadequate response to DMARDs.40
The  SATORI  trial  (Study  of Active    Controlled 
TOcilizumab  Monotherapy  for  Rheumatoid 
Arthritis  Patients  with  an  Inadequate  Response  to 
  Methotrexate) demonstrated that TCZ monotherapy 
showed    superior  ACR  response  criteria  compared 
with MTX plus placebo treatment for patients with 
an inadequate response to MTX.41
Phase IIIb/IV Clinical Studies
Following  phase  III  clinical  trials,  a  number  of 
additional  studies  (TAMARA,  DANBIO  registry, 
REACTION,  ROSE,  ACT-RAY,  ACT-SURE,  and 
ACT-STAR) were conducted to investigate the effi-
cacy of TCZ in clinical trials and daily clinical set-
tings (Table 3).
Compared with the EU and Japan, the recommended 
initial dosing of TCZ is low (4 mg/kg) in the USA. 
As shown in Figure 3, Cochrane review demonstrated 
that the efficacy of 4 mg/kg TCZ was inferior to that 
of  8  mg/kg  TCZ  under  monotherapy  condition.42 
Therefore, dose-escalation of TCZ is often necessary 
in  real  life  medical  practice.  A  dose-  escalation 
study  in  a  clinical  practice  setting  was  therefore 
conducted in the US. The dose of TCZ for DMARDs 
inadequate response (IR) and TNF-IR patients who 
did not achieve adequate response to 4 mg/kg TCZ 
at 16 weeks was escalated to 8 mg/kg TCZ. These 
patients  showed  significant  improvement  when 
evaluated at 24 weeks.43
In  Germany,  286  patients  were  registered  for 
the  TAMARA  (Tocilizumab  And  DMARDs: 
  Achievements in Rheumatoid Arthritis) study, which 
analyzed  the  effectiveness  and  safety  of  TCZ.44,45 
Of these patients, 41.6% had been previously treated 
with TNF inhibitors. The percentage of patients that 
achieved  DAS  remission  and  a  European  League 
Against  Rheumatism  (EULAR)  ‘good  response’ 
was  47.6%  and  54.9%,  respectively.  ACR50/70 
response rates at week 24 were 50.7% and 33.9%, 
respectively. The new ACR/EULAR Boolean-based 
criteria were 15.0% after 12 weeks and 20.3% after 
24 weeks.   Clinical Disease Activity Index (CDAI) 
and   Simplified Disease Activity Index (SDAI) remis-
sion rates were 24.1% and 25.2%, respectively.
In Denmark, 178 patients with RA that were treated 
with TCZ were identified in the   DANBIO (The   Danish 
Registry  for  Biologic Therapies  in    Rheumatology) 
registry.46 After 48 weeks, 64% of these patients were 
still  being  treated.  Among  patients  with  available 
response data, DAS28 was 5.4, 2.9 and 2.5 at baseline, 
week 24 and week 48,   respectively. The remission 
rates at weeks 24 and 48 were 39% and 58%, respec-
tively  and  EULAR  good  or    moderate  response 
rates  were  77%  and  84%,    respectively.  These 
response  rates  were  comparable  to  those 
found in patients switching to a second TNF inhibitor 
and to the response rates previously demonstrated in 
phase III clinical trials.
In  Japan,  229  patients  were  registered  in  the 
REACTION  (Retrospective  Actemra  Investigation 
for Optimal Needs of RA) study, which analyzed TCZ 
effectivity.47–49 DAS28 remission (DAS28 , 2.6) rates 
at 24, 52 and 104 weeks were 54%, 59% and 71%, 
respectively.  CDAI  remission  (CDAI  #  2.8)  rates 
at  24,  52,  104  weeks  were  15%,  22%,  and  37%, 
  respectively.  Structural  remission  (total  sharp 
score #0.5) and functional remission (health assess-
ment questionnaire #0.5) at 104 weeks were 53% 
and 38%, respectively. Thus, not only clinical remis-
sion but also structural and functional remission was 
maintained long-term.
These studies confirm both the short-term efficacy 
and  the  long-term  tolerability  of  TCZ  not  only 
in  RCTs  but  also  in  real  life  clinical  care.  In  the 
DAMBIO registry, the 2-year drug survival of patients 
treated with TCZ and TNF inhibitors was 70% and 
40%–60%,  respectively.46,50  We  also  demonstrated 
drug continuation rate of TCZ.51 The median survival 
of  patients  treated  with  TCZ,  infliximab  (IFX), 
etanercept (ETN) and adalimumab (ADA) was 2.7, 
1.7, 2.2 and 1.1 years, respectively. The survival rate 
of patients treated with TCZ was significantly higher 
than  that  of  patients  treated  with  TNF  inhibitors 
(P  ,  0.001).  These  results  indicate  that  survival 
following  treatment  with  TCZ  is  superior  to  that 
following TNF inhibitor treatment.
In the USA, 619 patients were registered in the 
ROSE  (The  Rapid  Onset  and  Systemic  Efficacy) Tocilizumab for the treatment of rheumatoid arthritis
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study for analysis of the efficacy and safety of TCZ.52 
This  study  was  a  24-week,  randomized,  double-
blind, placebo-controlled, parallel-group, multicenter 
phase IIIb clinical trial. The percentage of ACR20 
and ACR50 responders was significantly higher for 
TCZ-treated versus placebo-treated patients as early 
as week 4 and continued up to week 24. Compared 
to the placebo-treated patients, more patients in the 
TCZ group achieved ACR70 responses beginning at 
week 8 (P , 0.01). Safety findings were consistent 
with the known TCZ safety profile. Rapid improve-
ment in clinical outcomes was demonstrated as early 
as week 1 as shown by DAS28 scores, patient mea-
sures and CRP levels.
The ACT-RAY study was a double-blind 2-year 
phase IIIb study.53–55 In this study, 556 patients who 
were  on  stable  doses  of  oral  weekly  MTX  were 
randomly  divided  into  groups  that  were  treated 
with  either  8  mg/kg  TCZ  plus  continued  MTX 
(TCZ + MTX group) or were switched to 8 mg/kg 
TCZ  (TCZ  +  placebo  group).  Treatment  efficacy 
was evaluated at week 24. Five hundred and twelve 
patients (92%) completed the initial 24-week period. 
Of the TCZ + MTX group, 71.8%, 45.1% and 24.7% 
achieved ACR20, 50 and 70 responses, respectively 
and 40.4% achieved DAS remission. Of the TCZ + 
placebo group, 70.7%, 46.9% and 25.7% achieved 
ACR20, 50 and 70 response, respectively, and 34.8% 
achieved DAS remission. There were no differences 
in the ACR scores and DAS remission rates between 
the two groups. The onset of drug efficacy was rapid. 
Rates of AEs,   serious AEs, and serious infections per 
100 patient-years (PY) were 491, 21, and 6 for the 
TCZ + MTX group and 467, 18, and 6 for the TCZ 
group, respectively, with the most frequent AEs and 
serious AEs being infection. This study also analyzed 
X-ray and MRI changes after TCZ therapy. Structural 
analysis also indicated no difference between TCZ 
monotherapy and TCZ combined with MTX therapy.
The ACT-SURE  study  was  a  phase  IIIb,  open-
label,  single-arm,  6-month  study.56,57  In  this  study, 
1,681 patients with inadequate responses to DMARDs 
or  TNF  inhibitors  were  registered.  Patients  were 
randomly divided into groups that were treated with 
8 mg/kg TCZ alone every 4 weeks (TCZ monotherapy 
group) or 8 mg/kg TCZ in combination with DMARDs 
(TCZ  +  DMARDs  group)  and  were  evaluated  at 
24 weeks. Of the TCZ monotherapy group, 43.5% 
and  23.8%,  achieved  ACR50  and  70  responses, 
respectively, and 57.9%, 18.6% and 21.3% achieved 
DAS, CDAI and SDAI remission, respectively. Of the 
TCZ + DMARDs group, 47.2% and 26.8% achieved 
ACR50 and 70 responses, respectively and 49.8%, 
20.0% and 21.5% achieved DAS, CDAI and SDAI 
remission, respectively. Thus, TCZ as monotherapy 
showed the same efficacy as TCZ + DMARDs.
The ACT-STAR study was a 24-week, prospective, 
open-label study that was performed in the US. In this 
study,58,59 886 patients with moderate-to-severe active 
RA who had an inadequate response to current biologic 
or nonbiologic DMARDs were registered and divided 
into random groups that were treated with 4 mg/kg 
1000 100 10 1 0.1
TCZ (8) + MTX/DMARDs vs. MTX/DMARDs 3.79 (2.39 to 6.00)
TCZ (8) vs. MTX 3.14 (1.35 to 7.28)
TCZ (8) vs. placebo 21.2 (2.96 to 151.74)
TCZ (4) + MTX vs. MTX 2.59 (1.88 to 3.58)
TCZ (4) vs. MTX 0.97 (0.52 to 1.80)
TCZ (4) vs. placebo 13.74 (1.87 to 100.83)
Odds ratio (95% CI)
Favors tocilizumab
Figure 3. The summary of the efficacy of tocilizumab in phase III randomized controlled trials in RA patients. 
Notes: Cochrane review summarized the efficacy of tocilizumab (TCZ) from eight randomized controlled trials.42 These forest plots demonstrate odds ratio of 
achieving ACR 50 response rate. Efficacy of 8 mg/kg TCZ as monotherapy or in combination with MTX was significantly better than placebo or MTX in achiev-
ing ACR 50 response rates. Although the efficacy of 4 mg/kg TCZ monotherapy was not superior to MTX, that of 4 mg/kg with MTX can overcome MTX.Tocilizumab for the treatment of rheumatoid arthritis
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TCZ  +  DMARDs,  8  mg/kg  TCZ  +  DMARDs  or 
8 mg/kg TCZ monotherapy. At week 8, patients treated 
with 4 mg/kg TCZ + DMARDs who did not achieve 
ACR20 had their TCZ dose increased to 8 mg/kg. For 
patients on 8 mg/kg TCZ + DMARDs, the dose could be 
decreased any time for safety   reasons. Seven hundred 
and thirty one (82.5%) patients completed the study. 
Over half of the 4 mg/kg TCZ-treated patients were 
eventually switched to 8 mg/kg TCZ. Of the 4 mg/kg 
TCZ + DMARDs subgroup, 43.1%, 22.8% and 6.9% 
achieved ACR20, 50 and 70 responses, respectively at 
week 24 and 17.6% achieved DAS remission. In the 
8 mg/kg TCZ + DMARDs subgroup, 48.9%, 22.6% 
and  8.1%  achieved ACR20,  50  and  70  responses, 
respectively at week 24 and 22.8% achieved DAS 
remission.  In  the  8  mg/kg  TCZ  monotherapy 
subgroup, 47.3%, 20.9%, 8.1% achieved ACR20, 50 
and 70 responses, respectively at week 24 and 15.8% 
achieved DAS remission. Safety profiles and efficacy 
were  similar  for  the  TCZ  monotherapy  and  TCZ-
combination with DMARDs groups.
Remission  has  recently  become  the  current 
treatment  goal  for  RA.  An  increased  number  of 
patients have achieved this goal in clinical trials.60 
The  duration  of  TCZ  efficacy  after  cessation  of 
TCZ  treatment  following  DAS28  remission  was 
demonstrated in the DREAM (Drug free Remission 
after  cessation  of  Actemra  Monotherapy)  study.61 
Efficacy following cessation of TCZ treatment was 
35.1% and 13.4% at 24 and 52 weeks, respectively. 
Serum  levels  of  IL-6  and  MMP-3  are  useful 
markers for identifying patients who may be able to 
discontinue TCZ without acute disease flare-up. In 
addition, the result that TCZ could induce remission 
again  following  recurrence  after  TCZ  cessation 
was demonstrated by the RESTORE (Retreatment 
Efficacy and Safety to Tocilizumab in patients with 
rheumatoid arthritis at Recurrence) study.62
safety
Cochrane  review  summarized  the  safety  profile  of 
TCZ from 8 RCTs (3,334 participants; 2,233 treated 
with TCZ and 1,101 controls).42 It is demonstrated that 
patients treated with TCZ are 1.2 times more likely to 
have any AE (absolute%; 74% vs. 65%) and 0.6 times 
less likely to be withdrawn from treatment for any 
reason (absolute%; 8.1% vs. 14.9%). Nishimoto et al 
also reported the safety profile of TCZ monotherapy 
including 6 initial RCTs and 5 long-term extension 
studies in Japan.63 For these studies, 601 patients with 
a total exposure of 2,188 PY were enrolled. The medial 
treatment duration was 3.8 years. The incidence of 
AEs, including abnormal laboratory test results, was 
calculated  as  465.1/100  PY.  Infection  is  the  most 
common  serious  AE  (6.22/100  PY).    Furthermore, 
a systematic literature review to assess the risk of 
AEs for RA patients treated with TCZ reported that 
pooled odds ratios (ORs) indicated a statistically sig-
nificant increased risk of AEs for patients treated with 
8 mg/kg of TCZ plus methotrexate compared with 
controls (OR = 1.53; 95%CI = 1.26–1.86) in addi-
tion to a heightened risk of infection (OR = 1.30; 
95%CI = 1.07–1.58). However, no increase in the 
incidence of malignancy or hepatitis was detected.
The safety profile of TCZ combination therapy 
was reported in 2011.64 This analysis included 5 core 
phase III RCT, 2 ongoing extension trials, 1 clini-
cal pharmacology study and 2 patient populations; a 
control population (4,199) and a TCZ-treated popu-
lation (4,009). Overall AE and serious AE rates were 
278.2/100 PY and 14.4/100 PY, respectively. These 
events  included  serious  infections  (4.7/100  PY),   
opportunistic  infections  (0.23/100  PY),  gastroin-
testinal  perforations  (0.28/100  PY),  malignancy 
(1.1/100 PY), myocardial infarction (0.25/100 PY) 
and  stroke  (0.19/100  PY). Another  report  demon-
strated that analysis of the pooled ORs revealed a 
statistically significant increased risk of AEs in the 
8 mg/kg TCZ with MTX group compared with con-
trols (OR = 1.53; 95%CI = 1.26–1.86). The risk of 
infection was significantly higher in the 8 mg/kg TCZ 
with MTX group compared with controls (OR = 1.30; 
95%CI = 1.07–1.58). In contrast, no increased inci-
dence  of  malignancy,  tuberculosis  reactivation  or 
hepatitis was seen.65
The  safety  profile  of TCZ  in  real  life  medical-
care  in  Japan  was  reported  in  2011.66,67  In  Japan, 
all patients treated with TCZ were registered in the 
all-patient  postmarketing  surveillance  (JPMS-TCZ) 
program and were observed for 28 weeks. From April 
2008 to August 2010, 12,799 patients were registered 
in JPMS-TCZ. The interim analysis of 3,881 patients 
has been published66 and the final analysis of the 7,901 
patients of JPMS-TCZ was presented in ACR2011.67 
The incidence of total AEs and serious AEs was 43.9% 
and  9.6%,  respectively.  Infections  and  infestation Ogata et al
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were the most frequent AEs (11.1%) and serious AEs 
(0.5%). The incidence of serious AEs was higher in 
the patients whose disease duration was $10 years. 
The DAS and Boolean remission rate was higher in 
patients whose disease duration was ,2 years and 
the remission rate was higher in TNF inhibitor-naïve 
patients. Combining MTX with TCZ did not influence 
the remission rates. Surprisingly the serious AEs of 
TCZ monotherapy were slightly higher than those of 
TCZ and MTX combination therapy. The standard 
mortality ratio of TCZ (1.15; 95%CI = 1.12–2.46) 
was  comparable  with  that  of  a  standard  Japanese 
patient cohort (between 1.46; 95%CI = 1.32–1.60 and 
1.90; 95%CI: 1.75–2.07).68
Long-term  safety  was  also  analyzed  in  RCTs.69 
Rates  of  serious  AEs,  serious  infections,  and 
cardiovascular  events  have  remained  stable  with 
continued  exposure  to  TCZ  in  long-term  clinical 
trials. Infection was the most frequent serious AE. 
The  most  commonly  reported  infections  in  RCT 
were pneumonia (0.9/100PY) and skin or soft tissue 
infections (0.9/100PY). The rates of serious infections 
remained stable for 5 years indicating that continued 
administration of TCZ did not increase the risk of 
such infections.
In the JPMS-TCZ study, the rate of serious respi-
ratory infections was 1.77/100 PY in the TCZ cohort 
and  0.53/100  PY  in  a  standard  Japanese  patient 
cohort.70 The standardized incidence ratio (SIR) of 
serious respiratory infection in the TCZ cohort was 
2.35 (95%CI = 1.66–3.24), standardized for age, sex 
and  corticosteroid  use.  This  risk  was  comparable 
with  that  associated  with  TNF  inhibitors. As  with 
other biologics, careful observation is necessary dur-
ing administration of TCZ. In particular, TCZ has a 
strong down-regulatory effect on acute-phase reac-
tants such as CRP. As a result, the consensus opinion 
issued a special caution that CRP cannot be used as 
a diagnostic indicator for early infections in patients 
treated with TCZ.71 White blood cell count and neu-
trophil counts are usually decreased, especially just 
after TCZ injection, but this decrease was not related 
to the incidence of infection.72
Tuberculosis  and  opportunistic  infections  have 
been observed in clinical trials of TCZ (0.3/100PY).70 
However, half of these events were reported as non-
serious  infections. The  reactivation  of  tuberculosis 
is a major concern during TNF inhibitor treatment.73 
In a mouse model, anti-IL-6R  Ab-treated mice survived 
for more than 200 days after TB challenge, whereas 
the anti-TNF-α Ab-treated mice all died between 120 
and 181 days.74 In addition, interferon (IFN)-γ induc-
tion by the tuberculosis antigen was suppressed in the 
presence of TNF inhibitors (IFX and ETN) but not in 
the presence of TCZ.75 Although it seems likely that 
the incidence of reactivation of tuberculosis is lower 
during TCZ treatment, further detailed study will be 
needed to clarify this point. The consensus opinion 
recommended that patients should be screened for 
tuberculosis. Some cases of localized Herpes zoster 
infection occurred in clinical trials, but the relation-
ship  between TCZ  administration  and  these  infec-
tions  was  unclear.  Patients  with  active  hepatitis 
C or B were excluded from the clinical trials, so no 
data has been reported regarding TCZ and HBV or 
HCV infections.
Clinical trials and the above-mentioned combined-
analysis showed that the rate of gastrointestinal perfo-
ration following TCZ treatment was 0.26/100 PY.69 In 
the JPMS-TCZ study, 7 gastrointestinal perforations 
were reported in 6 patients.66 In the worldwide Roche 
clinical trials, 26 (0.65%) cases of gastrointestinal per-
foration were found among patients with RA treated 
with TCZ at a rate of 1.9/1,000 PY and most cases 
appeared to be complications of diverticulitis.76 This 
rate lies between the reported rate of gastrointestinal 
perforations  for  corticosteroids  (3.9/1,000  PY)  and 
TNF inhibitors (1.3/1,000 PY) in the United Health 
Care database. The concomitant use of corticosteroids 
or non-steroid anti-inflammatory drugs with TCZ may 
increase this risk. The consensus opinion states that 
TCZ should be used in caution in patients with history 
of GI perforation, intestinal ulcers or diverticulitis.
Increases in mean fasting levels of plasma lipids 
such  as  total  cholesterol,  low-density  lipoprotein, 
triglycerides  and  high-density  lipoprotein,  were 
seen  in  20%–30%  of  patients  treated  with  TCZ. 
The increase in lipid level resulting from TCZ treat-
ment is perhaps mediated by an affect on lipoprotein 
receptor expression, since it has been recently shown 
that overproduced IL-6 decreases blood lipid levels 
via upregulation of the very-low-density lipoprotein 
(VLDL) receptor.77 The consensus opinion recom-
mended that lipid levels be monitored 1–2 month 
after initiation of treatment and then every 6 months. 
In spite of the elevation of lipids, combined analysis Tocilizumab for the treatment of rheumatoid arthritis
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of  the  data  of  clinical  trials  showed  no  apparent 
increase in cardiac events in a follow-up of up to 
5 years. In the analysis, rates of myocardial infarc-
tion (0.3/100 PY) and stroke (0.2/100 PY) did not 
exceed the expected rates of RA patients.69 In con-
trast, oxidative stress was extremely low in patients 
with RA treated with TCZ.78 Moreover, hemoglobin 
(Hb) A1c levels and insulin sensitivity were improved 
by TCZ treatment.79,80
Combined-analysis showed that the overall ratio 
of  malignancy  occurrence  during  TCZ  treatment 
was 1.2/100 PY.69 This ratio did not increase with 
the duration of TCZ treatment over a median dura-
tion of 3.6 years. Furthermore, the SIR for malig-
nancy was 1.1/100 PY, which was considered to be 
within the range expected of RA patients. Although 
there is no report regarding increased incidences of 
malignancy during TCZ therapy, the use of TCZ for 
treatment of RA patients with malignancy cannot be 
recommended.
Many  patients  treated  with  TCZ  have  shown  a 
decrease in absolute neutrophil count. This decrease 
usually  occurs  early  after  administration  and  is 
  transient. There was no clear relationship between 
this neutropenia and an increase in infections.72 The 
consensus recommended that complete blood counts 
should be monitored regularly (every 4–8 weeks).
Hepatic aminotransferase such as L-aspartate ami-
notransferase (AST) and L-alanine aminotransferase 
(ALT) and bilirubin elevations may occur in patients 
treated with TCZ. In the JPMS-TCZ study, abnormal 
hepatic function was observed in 8.5% and 5.5% of 
TCZ-treated patients with or without MTX.66,67   Bilirubin 
elevations, mostly indirect, may occur independently. 
Liver function should be monitored regularly.
Serious infusion reactions related to TCZ treat-
ment are rare. In the combined analysis, 8 out of a 
total of 4,009 patients showed anaphylactic infusion 
reactions.69 Most of infusion reaction of TCZ occurs 
the beginning of TCZ therapy.
The safety of surgical intervention in patients with 
RA treated with TCZ has been reported.81   Postoperative 
surgical site infections were not increased during TCZ 
therapy. TCZ is recommended to be withheld at least 
14 days before major surgical procedures.69
There  are  no  data  available  regarding  the  safety 
of  TCZ  treatment  during  pregnancy  and  lactation. 
Although IL-6-deficient mice are perfectly viable,82 IL-6 
was reported to reduce recurrent abortion in an animal 
model.83 However, the effect of TCZ on embryonic and 
fetal development is unknown. At present the use of 
TCZ throughout pregnancy cannot be recommended.
Place in Therapy
A number of biologics are currently available for the 
treatment  of  RA,  including  TNF  inhibitors  (inflix-
imab; IFX, etanercept; ETN, adalimumab; ADA, goli-
mumab; GOL, and certolizumab pegol; CEL), an IL-1 
antagonist (anakinra; ANK), a B-cell depletor (ritux-
imab; RTX), an IL-6 receptor inhibitor (TCZ), and a 
T-cell activation blocker (abatacept; ABA). While all 
of these biologics have proven effectiveness in RCTs, 
very  limited  head-to-head  comparative  studies  are 
available. Recently, meta-analysis has allowed indi-
rect comparisons between TCZ and other biologics. 
Bergman et al reported such an indirect comparison of 
TCZ and other biologics.84 The effectiveness of TCZ 
appeared to be comparable to that of other biologics 
(ABA, ADA, ETN, IFX and RTX) in terms of ACR20 
and ACR50 responses. Turkstra et al reported a mixed 
treatment comparison of the short-term efficacy of nine 
biologics (ABA, ADA, ANK, CEL, ETN, GOL, IFX, 
RTX, and TCZ) in patients with established RA.85 As 
shown in Figure 4, the ACR50 response rate of TCZ at 
6 months is comparable to that of ABA, ADA, ETN, 
GOL, IFX and RTX. ANK is inferior to TCZ and 
CEL may be superior to TCZ. Salliot et al reported 
an indirect comparison of the efficacy of TCZ in RA 
patients with inadequate response to TNF inhibitors 
(ADA, ETN and IFX).86 No significant difference was 
found between TCZ and other biologics (ABA, GOL, 
and RTX). A comparison of AEs of nine biologics was 
reported in Cochrane review.87 As shown in Figure 5, 
serious AEs of TCZ were comparable to those of other 
biologics except for ABA and ANK. These indicate 
that the efficacy and tolerability of TCZ is compa-
rable to TNF inhibitors. Although TNF inhibitors are 
now recommended as first-line biologics,88 TCZ also 
has a potential capacity as a first-line biologic for RA 
patients who cannot use sufficient MTX, or is appro-
priate for the treatment of RA patients with secondary 
failure of TNF inhibitors. In the real world of rheuma-
tology practice, there are RA patients who cannot use 
sufficient MTX because of AEs. TEMPO89 and PRE-
MIER90 studies demonstrated no substantial differences 
in clinical responses between TNF inhibitors used as Ogata et al
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monotherapy  (ETN  and ADA)  and  MTX.91  British 
Society  for  Rheumatology  Biologics  Register 
(BSRBR)  also  concluded  better  responses  of  TNF 
inhibitors, when used in combination with MTX, than 
those used as monotherapy.92 In contrast, ACT-RAY,   
ACT-SURE and ACT-STAR indicated that there was 
no difference of the efficacy between TCZ monother-
apy and that with MTX.53–59 These results suggest that 
TCZ has advantage for the treatment of RA patients 
who are not tolerable to receive MTX, since TCZ pro-
vides the excellent efficacy even without concomitant 
use of MTX.
In the real world of rheumatology practice, there are 
also RA patients who fail to respond to TNF   inhibitors 
(primary  failure)  or  lose  response  to  them  (second 
Etanercept
Certolizumab pegol 3.08 (1.45 to 7.73)
1.18 (0.63 to 2.68)
0.68 (0.24 to 3.26) Golimumab
Anakinra 0.26 (0.11 to 0.80)
0.59 (0.32 to 1.29) Infliximab
Adalimumab 0.50 (0.27 to 1.04)
0.60 (0.29 to 1.53) Rituximab
Abatacept 0.67 (0.35 to 1.45)
Odds ratio (95% CI)
Favors other biologics Favors tocilizumab
10 1.0 0.1
Figure 4. Indirect comparison of the efficacy of toclizumab and other biologics in RA.
Notes: Indirect comparison of ACR50 response rate at 6 months-treatment of biologics (tocilizumab vs. 8 other biologics).85 The efficacy of tocilizumab 
is comparable to other biologics except for certolizumab pegol and anakinra. Other analyses of the efficacy (tocilizumab vs. TNF inhibitors) show similar 
results.84,86
failure).93  In  such  case,  the  switching  of  biologics  is 
required.  However,  the  probability  of  responding  to 
a second TNF inhibitor is lower than that of respond-
ing to the first one.94 For patients with primary failure 
it is conceivable that TNF may not be a major effector 
cytokine, so that change of target from TNF to non-TNF 
molecules including IL-6 is reasonable. TCZ is also effi-
cacious for patients with second TNF failure.38,44,45,56–59 
These findings indicate TCZ is a good indication for the 
treatment of RA patients who are intolerable to MTX or 
non-responders to TNF inhibitors. Finally, it is worthy of 
describing here that clinical trial of subcutaneous injec-
tion of TCZ is currently undergoing. If the subcutaneous 
TCZ injection will bring the similar efficacy to the intra-
venous one, it would be convenient for patients.
Odds ratio (95% CI)
Favors other biologics
10 1.0 0.1
Etanercept
Certolizumab pegol 1.16 (0.92 to 2.24)
0.98 (0.56 to 1.72)
0.85 (0.44 to 1.62) Golimumab
Anakinra 0.44 (0.20 to 0.99)
1.04 (0.60 to 0.78) Infliximab
Adalimumab 0.79 (0.45 to 1.40)
0.88 (0.50 to 1.33)
0.88 (0.50 to 1.55)
Rituximab
Placebo
Abatacept 0.52 (0.27 to 0.99)
Favors tocilizumab
Figure 5. Indirect comparison of serious adverse events of tocilizumab and other biologics in RA.
Notes: Indirect comparison of serious adverse events of biologics (tocilizumab vs. 8 other biologics and placebo).87 The safety profile of tocilizumab is 
comparable to other biologics except abatacept and anakinra.Tocilizumab for the treatment of rheumatoid arthritis
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Conclusion
IL-6  is  a  key  cytokine  in  immune  activation  and 
inflammation. TCZ exerts a blocking effect on IL-6 
function and exhibits excellent efficacy and tolerabil-
ity for RA treatment. Because of limited evidence of 
TCZ in the USA, at the present time the ACR recom-
mendations for the treatment of RA does not recom-
mend TCZ as a first-line biologic. However, recent 
advance indicates that TCZ has a certain advantage 
for patients who cannot use MTX or fail to respond 
to TNF inhibitors. We believe that TCZ possesses a 
capacity as a first-line biologic for the treatment of 
RA patients, although further clinical experience of 
TCZ will be required.
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